Sex-Specific Survival and Treatment Delay in Oropharyngeal Squamous Cell Carcinoma.
head and neck squamous cell carcinoma
human papillomavirus
oropharyngeal squamous cell carcinoma
sex‐based disparities
treatment delay
unknown primary
Journal
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
ISSN: 1097-6817
Titre abrégé: Otolaryngol Head Neck Surg
Pays: England
ID NLM: 8508176
Informations de publication
Date de publication:
28 Apr 2024
28 Apr 2024
Historique:
revised:
28
03
2024
received:
05
01
2024
accepted:
07
04
2024
medline:
28
4
2024
pubmed:
28
4
2024
entrez:
28
4
2024
Statut:
aheadofprint
Résumé
As the majority of oropharyngeal squamous cell carcinoma (OPSCC) is diagnosed in males, outcomes among females are not well-characterized. We identify sex-specific factors in OPSCC to refine female prognostication. Retrospective cohort. National Cancer Database (NCDB). OPSCC cases from the 2004 to 2019 NCDB were identified. Sociodemographic, clinical, and treatment characteristics (including timing between diagnosis and treatment administration) were compared between sexes. Multivariable Cox proportional hazard regression models were constructed to characterize survival in overall and female-only cohorts. Similar multivariable binomial logistic regression and survival models were constructed to assess odds of treatment delays and their effects on survival, respectively. A total of 192,973 OPSCC patients were identified; 36,695 (19%) were female. Females had more human papillomavirus (HPV) negative, lower clinical T and N stage, and higher comorbidity disease. Females experienced lower survival in HPV negative (hazard ratio, HR = 1.11, P < .001) but not HPV-positive disease. Females were more likely to have any treatment initiated over the median of 28 days (odds ratio, OR = 1.04, P = .014) or delays in adjuvant radiotherapy initiation over 6 weeks (OR = 1.11, P = .032). Treatment delay over 60 days (HR = 1.17, P = .016) and delay in adjuvant therapy initiation (HR = 1.24, P = .02) were associated with worse survival among females. In one of the largest analyses of OPSCC, females had poorer survival than males, specifically in HPV-negative disease, despite presentation with less advanced disease. Notably, delays in any treatment initiation and adjuvant radiotherapy initiation were more likely in HPV-negative women and associated with worse survival, highlighting potential systemic weaknesses contributing to poor prognosis among females.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Academy of Otolaryngology–Head and Neck Surgery Foundation.
Références
Lechner M, Liu J, Masterson L, Fenton TR. HPV‐associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19(5):306‐327. doi:10.1038/s41571-022-00603-7
Amin MB, Edge SB, Greene FL, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
Kao DD, Ferrandino RM, Marshall DC, et al. Sex‐related differences in outcomes for oropharyngeal squamous cell carcinoma by HPV status. Int J Otolaryngol. 2022;2022:1‐10.
Park A, Alabaster A, Shen H, Mell LK, Katzel JA. Undertreatment of women with locoregionally advanced head and neck cancer. Cancer. 2019;125(17):3033‐3039. doi:10.1002/cncr.32187
Faraji F, Rettig EM, Tsai HL, et al. The prevalence of human papillomavirus in oropharyngeal cancer is increasing regardless of sex or race, and the influence of sex and race on survival is modified by human papillomavirus tumor status. Cancer. 2019;125(5):761‐769.
Li H, Park HS, Osborn HA, Judson BL. Sex differences in patients with high risk HPV‐associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas. Cancers Head Neck. 2018;3(1):4. doi:10.1186/s41199-018-0031-y
Razzaghi H, Saraiya M, Thompson TD, Henley SJ, Viens L, Wilson R. Five‐year relative survival for human papillomavirus‐associated cancer sites. Cancer. 2018;124(1):203‐211. doi:10.1002/cncr.30947
Hunter WP, Harris JA, Lee CC, Cheng AC, Peacock ZS. Females have worse overall and disease‐specific survival in human papillomavirus‐negative oropharyngeal squamous cell carcinoma. J Oral Maxillofac Surg. 2022;80(7):1260‐1271. doi:10.1016/j.joms.2022.03.017
Su WW, Lee YH, Yen AM, et al. Impact of treatment delay on survival of oral/oropharyngeal cancers: results of a nationwide screening program. Head Neck. 2021;43(2):473‐484.
Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21(3):555‐563. doi:10.1200/JCO.2003.04.171
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers. National Comprehensive Cancer Network; 2023.
Rotsides JM, Oliver JR, Moses LE, et al. Socioeconomic and racial disparities and survival of human papillomavirus‐associated oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2021;164(1):131‐138. doi:10.1177/0194599820935853
Tsai MH, Cheng YJ, Pao TH, Hsueh WT, Chen HHW, Wu YH. Association of primary treatment modality for advanced‐stage oropharyngeal squamous cell carcinoma with survival outcomes. JAMA Netw Open. 2021;4(6):e2112067.
Kelly JR, Park HS, An Y, et al. Comparison of survival outcomes among human papillomavirus‐negative cT1‐2 N1‐2b patients with oropharyngeal squamous cell cancer treated with upfront surgery vs definitive chemoradiation therapy: an observational study. JAMA Oncol. 2017;3(8):1107‐1111.
Kelly JR, Park HS, An Y, et al. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus‐associated oropharyngeal squamous cell cancer. Oral Oncol. 2018;79:64‐70.
Nauta IH, Rietbergen MM, Van Bokhoven AAJD, et al. Evaluation of the eighth TNM classification on p16‐positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann Oncol. 2018;29(5):1273‐1279.
Liu C, Mann D, Sinha UK, Kokot NC. The molecular mechanisms of increased radiosensitivity of HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg. 2018;47(1):59. doi:10.1186/s40463-018-0302-y
Megwalu UC, Ma Y. Racial disparities in oropharyngeal cancer stage at diagnosis. Anticancer Res. 2017;37(2):835‐840.
Bozec A, Culié D, Poissonnet G, Demard F, Dassonville O. Current therapeutic strategies in patients with oropharyngeal squamous cell carcinoma: impact of the tumor HPV status. Cancers. 2021;13(21):5456.
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24‐35.
Nieminen M, Atula T, Bäck L, Mäkitie A, Jouhi L, Aro K. Factors influencing patient and health care delays in oropharyngeal cancer. J Otolaryngol Head Neck Surg. 2020;49(1):22. doi:10.1186/s40463-020-00413-w
Unger JM, Fleury M. Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer. J Clin Oncol. 2021;39(28_suppl):74. doi:10.1200/JCO.2020.39.28_suppl.74
Lechner M, Jones OS, Breeze CE, Gilson R. Gender‐neutral HPV vaccination in the UK, rising male oropharyngeal cancer rates, and lack of HPV awareness. Lancet Infect Dis. 2019;19(2):131‐132.
Graboyes EM, Halbert CH, Li H, et al. Barriers to the delivery of timely, guideline‐adherent adjuvant therapy among patients with head and neck cancer. JCO Oncol Pract. 2020;16(12):e1417‐e1432. doi:10.1200/OP.20.00271